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SUMMARY
Objective—In three U.S. state public health laboratories (PHLs) using a fourth-generation 
immunoassay (IA), an HIV-1/HIV-2 differentiation antibody IA and a nucleic acid test (NAT), we 
characterized the yield and time to reporting of acute infections, and cost per positive specimen.
Methods—Routine HIV testing data were collected from July 1, 2012-June 30, 2013 for 
Massachusetts and Maryland PHLs, and from November 27, 2012-June 30, 2013 for Michigan 
PHL. Massachusetts and Michigan used fourth-generation and differentiation IAs with NAT 
conducted by a referral laboratory. In Maryland, fourth-generation IA repeatedly reactive 
specimens were followed by a Western blot (WB), and those with negative or indeterminate results 
were tested with a differentiation IA and HIV-1 NAT, and if positive by NAT, confirmed by a 
different HIV-1 NAT. Specimens from WB-positive persons at risk for HIV-2 were tested with a 
differentiation IA and, if positive, with an HIV-2 WB and/or differential HIV-1/HIV-2 proviral 
DNA polymerase chain reaction.
Results—Among 7,914 specimens from Massachusetts PHL, 6,069 from Michigan PHL, and 
36,266 from Maryland PHL, 0.10%, 0.02% and 0.05% acute infections were identified, 
respectively. Massachusetts and Maryland PHLs each had 1 HIV-2 positive specimen. The median 
time from specimen receipt to laboratory reporting of results for acute infections at Massachusetts, 
Michigan and Maryland PHLs was 8, 11, and 7 days respectively. The laboratory cost per HIV 
positive specimen was $336 (Massachusetts), $263 (Michigan) and $210 (Maryland).
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Conclusions—Acute and established infections were found by PHLs using fourth-generation IA 
in conjunction with antibody tests and NAT. Time to reporting of acute HIV test results to clients 
was suboptimal, and needs to be streamlined to expedite treatment and interrupt transmission.
Keywords
Fourth-generation immunoassay; Acute infections; Cost; HIV testing algorithms; Time to 
reporting
INTRODUCTION
In 2014, the Centers for Disease Control and Prevention (CDC) and the Association of 
Public Health Laboratories (APHL) recommended an HIV diagnostic testing algorithm [1]: 
fourth-generation immunoassay (IA) followed, when repeatedly reactive, by an HIV-1/HIV-2 
differentiation antibody IA. When that test is negative or indeterminate, an HIV-1 nucleic 
acid test (NAT) is conducted. Positive NAT results indicate acute infection. Relative to the 
CDC algorithm from 1989 [2] which used an antibody-based supplemental test (i.e., Western 
blot or immunofluorescence assay), the recommended algorithm detects HIV-1 infection 
earlier, and distinguishes HIV-1 from HIV-2 infections [1, 3–7]. With the availability of 
fourth-generation IAs that detect p24 antigen and HIV-1 and HIV-2 antibodies [8] 
approximately 80% of acute HIV infections can be detected that would otherwise only be 
detectable by NAT [9–11]. The commercial availability of fourth-generation HIV-1/2 assays 
makes simultaneous screening for both acute and established HIV infections feasible for 
most clinical laboratories in the United States. Fourth-generation IAs perform with high 
specificity [7, 10, 12–14]; as a result, they are unlikely to have false-positive results when 
used in the recommended algorithm.
Assessing the performance of the CDC/APHL HIV diagnostic testing algorithm in U.S. state 
public health laboratories (PHLs) is critical to ensuring its successful implementation in the 
United States. Little information on turn-around time has been published from laboratories 
using the algorithm. Timely reporting of HIV test results to clients in the acute stage of HIV 
infection is important to decrease transmission potential by initiating antiretroviral therapy 
early [15]. Additionally, there are limited data on the cost of the recommended algorithm, 
which will impact its future uptake in U.S. state PHLs [16]. Therefore, in three U.S. PHLs, 
we characterized the yield of acute infections, time to reporting of acute and antibody-
positive HIV-1 infections, and cost per HIV positive specimen.
METHODS
Setting
Routine HIV testing data were collected from July 1, 2012- June 30, 2013 for Massachusetts 
and Maryland PHLs, and from November 27, 2012- June 30, 2013 for Michigan PHL. 
Maryland and Massachusetts PHLs reported data from clinical testing sites (e.g., sexually 
transmitted infections clinics, correctional facility clinics, community health centers, and 
inpatient hospitals) and nonclinical testing sites (e.g., HIV testing sites, schools, and 
shelters), and Michigan PHL reports data from clinical settings. Massachusetts and 
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Michigan used the CDC/APHL-recommended HIV diagnostic algorithm (Figure 1) with the 
following tests: GS HIV Combo Ag/Ab IA (Bio-Rad Laboratories, Redmond, WA) (GS 
Combo) [17], Multispot HIV-1/HIV-2 rapid test (Bio-Rad Laboratories, Redmond, WA) 
(Multispot) [18], and HIV-1 NAT (APTIMA HIV-1 RNA Qualitative Assay [Gen-Probe Inc., 
San Diego, CA]) [19]. The APTIMA HIV-1 RNA Qualitative Assay is the only NAT test 
approved for HIV diagnostic testing. Massachusetts PHL sent specimens needing HIV-1 
NAT to the Rhode Island Department of Health, State Health Laboratories, and Michigan 
PHL sent specimens to Florida Bureau of Public Health Laboratories, Jacksonville, FL as 
part of a CDC/APHL HIV-1 NAT demonstration project [20].
The Maryland PHL used a modified algorithm (Figure 2). ARCHITECT HIV Ag/Ab Combo 
(Abbott Diagnostics, Abbot Park, IL) (ARCHITECT) [21] was followed, when repeatedly 
reactive, by GS HIV-1 Western blot (Bio-Rad Laboratories, Redmond, WA) (WB) [22].
Specimens with negative or indeterminate WB results were tested with Multispot and in-
house developed and validated real-time polymerase chain reaction (PCR)-based HIV-1 
NATs [23–26]. If the initial NAT targeting the LTR gene was positive, two additional HIV-1 
NATs targeting pol and gag gene targets were performed. The presence and relative 
concentration of HIV-1 RNA in the HIV-1 NAT-positive sera were then confirmed using an 
off-label validated method of a commercially available HIV-1 viral load assay (VERSANT 
HIV-1 RNA 3.0 Assay [bDNA] [U.S. IVD] Siemens Health Care Tarrytown, NY). 
Specimens with positive HIV-1 WB results at increased risk for HIV-2 were tested with 
Multispot. HIV-2 positive specimens by Multispot were tested with a differential HIV-1/
HIV-2 proviral DNA PCR [27, 28] and/or an HIV-2 WB (SIV Western blot Assay 
[ZeptoMetrix Corporation, Buffalo, NY]) [29].
HIV testing outcomes
For each PHL, we determined the total number of non-reactive and repeatedly reactive 
specimens using the fourth-generation IA. Among repeatedly reactive specimens, we 
classified testing outcomes as confirmed HIV-1 antibody positive, acute infection, IA false 
positive, or HIV-2 positive. Specimens were classified as confirmed HIV-1 antibody positive 
if the WB or Multispot was HIV-1 positive. They were labeled as acute infections if the 
fourth-generation IA was repeatedly reactive, the WB or Multispot was negative or 
indeterminate, and the NAT was reactive. They were labeled as IA false positive if the 
specimen was fourth-generation IA repeatedly reactive, the WB or Multispot was negative or 
indeterminate, and NAT was not reactive. The specimen was labeled as HIV-2 positive based 
on Multispot results in Massachusetts and Michigan PHLs and based on Multispot, HIV-2 
WB or differential HIV-1/HIV-2 proviral DNA conventional PCR results in Maryland. We 
also calculated the specificity of the fourth-generation IA in each PHL.
Time to reporting of HIV test results
In each PHL, we determined the time from specimen collection to receipt in the laboratory, 
and from receipt in the laboratory to reporting of test results for HIV-1/2 negative specimens 
as well as for acute and HIV-1 antibody positive specimens. For Massachusetts and 
Maryland, we calculated the time from reporting of positive test results by the laboratory to 
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receipt of those results by clients separately for acute and HIV-1 antibody positive 
specimens, and the total time from specimen collection to receipt of positive test results by 
clients. For Maryland PHL, data on the receipt of test results by clients were only available 
for HIV tests conducted as part of an HIV Counseling Testing and Referral Program, and the 
delivery of results was based on direct report by the testing agency. The acute results are 
usually delivered by local health department disease intervention specialists who conduct 
field investigations of all acute diagnoses. For Massachusetts PHL, result and date provided 
are entered by client code on service forms under HIV testing information, and any negative 
values for time to reporting of HIV test results to clients were set to missing during the 
analysis.
Cost per HIV positive infection
In each PHL, we determined the total laboratory testing and labor costs per HIV-positive 
specimen. We collected the cost incurred for each test used in their algorithm. For each test, 
we collected the test kit brand, cost and size, frequency and number of controls per run, and 
typical run size. We calculated an adjusted cost per test by adding total kit cost and the cost 
of extra controls (if applicable), and dividing by the number of tests not used as controls. 
The total testing costs were obtained by summing the product of the adjusted costs per test 
and the number of specimens tested with that test. The total labor costs were summed for 
each test. Labor costs per test were calculated from the product of the labor hours per 
specimen, the total number of specimens tested, and the labor cost per hour. This was 
summed for all tests in the algorithm. The labor hours for each test were calculated either by 
being directly observed at the laboratory or from estimates from literature [16], and was 
divided by the number of specimens in a run. Labor hours included test processing times, 
time to prepare for testing the samples as well as time to report the results. Labor hours of 
the ARCHITECT at Maryland PHL were estimated to be 2.2 hours, and labor hours of the 
semi-automated GS Combo at Michigan and manual GS Combo at Massachusetts PHLs 
were estimated on average to be 1.4 and 3.9 contact hours respectively. The WB was 
estimated to take 3 contact hours [16] and the Multispot was estimated to take 0.5 contact 
hours. The labor cost per hour was estimated from the Bureau of Labor Statistics' estimate 
for the 2013 mean salary (including benefits) per hour of a laboratory technologist in each 
PHL's state [30]. The cost per positive in each of the PHL was calculated by summing 
laboratory testing and labor costs and dividing by the number of HIV-1 and 2 positive 
specimens. The cost per specimen in each PHL was calculated by summing laboratory 
testing and labor costs and dividing by the number of specimens tested. We did not include 
start-up costs or fixed costs such as space and overhead or non-laboratory variable costs 
associated with HIV testing such as the cost of specimen collection/phlebotomy and 
disclosure of HIV test results. All costs are reported in 2013 US dollars.
The project was approved by the Institutional Review Board of each State PHL. The CDC 
approved the project as post-marketing surveillance because routine de-identified data was 
submitted to the CDC by the contractor, John Snow Inc.
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Among 7,914 specimens tested from Massachusetts PHL, 6,069 from Michigan PHL and 
36,266 from Maryland PHL, 246 (3.11%), 163 (2.68%), and 983 (2.71%) HIV-1 antibody-
confirmed infections, and 8 (0.10%), 1 (0.02%) and 19 (0.05%) acute infections were 
identified, respectively (Table 1). For Massachusetts and Maryland PHL, 1 specimen each 
was identified as HIV-2 positive. There were 7 (0.09%), 5 (0.08%) and 29 (0.08%) 
specimens identified as false positive in Massachusetts, Michigan, and Maryland PHL 
respectively. The specificity of the fourth-generation IAs used in each of the three PHLs was 
99.9%.
Time to reporting of HIV test results
The median time from specimen receipt to laboratory reporting of test results for HIV-1 
antibody-confirmed infections was 3, 2 and 3 days, and for acute infections was 8, 11 and 7 
days for Massachusetts, Michigan, and Maryland PHLs respectively (Table 2). In 
Massachusetts and Maryland PHLs, the median time from specimen collection to receipt of 
test results by client for HIV-1 antibody-confirmed infections was 8 and 14 days, and for 
acute infections were 10 and 13 days respectively.
Cost per HIV positive infection
The unadjusted and adjusted testing costs, labor costs and total costs by test in each 
participating PHL are shown in Table 3. Overall, the cost per HIV-positive specimen was 
$336 in Massachusetts PHL, $263 in Michigan PHL and $210 in Maryland PHL. The cost 
per specimen tested was $10 in Massachusetts PHL, $7 in Michigan PHL and $5 in 
Maryland PHL.
DISCUSSION
In the current study, acute infections were detected in all laboratories, highlighting the utility 
of using fourth-generation assays in a variety of settings in the United States. Unlike the 
previous algorithm, which only detected established HIV-1 infection, the current algorithm 
works well in high-risk individuals [4], and detects acute [3, 7] and established HIV-1 
infections [5]. It also correctly identifies HIV-2 infections that would be missed or 
misclassified as HIV-1 by WB [6, 31]. The current study provides further evidence that 
using the recommended algorithm in U.S. PHLs can help in diagnosing infections early, 
although fourth-generation IAs detect approximately 80% of acute HIV infections [9–11].
Our study showed that the median time from specimen receipt to laboratory reporting of test 
results for acute infections was at least 7 days in the three PHLs, and for Massachusetts and 
Maryland PHL the median time from specimen collection to receipt of test results by clients 
for acute infections was 10 and 13 days respectively. However, documentation of the receipt 
of test results was not available for many infected individuals. Individuals in the acute stage 
of HIV infection are usually highly viremic, resulting in more virus shedding at mucosal 
sites, and are therefore more likely to transmit HIV infection through bodily secretions [32]. 
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Data from previous studies suggest that the rate of sexual transmission during acute 
infection is up to 26 times as high as that during established HIV-1 infection [33]. Similarly, 
it has been estimated that the proportion of total HIV transmissions attributable to early 
infections ranges between 6% and 49.4% [34–36]. Massachusetts Department of Public 
Health reported that the recommended algorithm reduced the time to reporting of HIV test 
results for antibody-positive specimens by 1 week compared with their previous algorithm 
[37]. Nonetheless, time to reporting of acute HIV test results to clients was suboptimal, and 
needs to be streamlined for timely interruption of transmission. Further, in order to use the 
recommended algorithm to its full advantage to detect early infections and reduce 
transmissions, PHLs must be prepared to conduct NAT with rapid turn-around. More 
affordable NAT options, such as diagnostic point of care NATs, are needed in the U.S. to 
rapidly identify acute infections. Public health systems must be in place to conduct timely 
linkage to medical care and partner services [38].
Estimating the cost per positive of the HIV diagnostic algorithm is challenging because of 
differences in laboratory HIV testing practices and volumes, and the prevalence of 
established and acute HIV infections [16]. Maryland PHL likely had the lowest cost per 
positive as compared to Massachusetts and Michigan PHLs because of the high number of 
confirmed HIV-1 antibody tests. However, when estimating the cost per specimen, the cost 
was still lowest for Maryland followed by Michigan and Massachusetts probably because of 
the lower adjusted cost for the screening test. High-volume laboratories are more likely to 
access volume pricing of the screening IAs than medium-volume laboratories [16]. In terms 
of the supplemental tests, Massachusetts ran controls each time the Multispot was run, 
which increased the cost but provided results to clients in a faster time frame for action at 
that site. However, Maryland and Michigan PHLs batched Multispot, which decreased their 
cost per HIV-positive specimen, but increased turn-around time. PHLs should assess whether 
excess controls are being used and develop an Individualized Quality Control Plan [39] for 
Multispot that follows the manufacturer's package insert. As in the Maryland PHL, a 
previous study has shown that for HIV-antibody positive specimens, laboratory costs in 
medium- (<50,000 IAs/year) and high-volume (≥50,000 IAs/year) laboratories for the 
recommended algorithm were generally less than those for the previous algorithm [16]. NAT 
is expensive, but only has to be used after a reactive fourth-generation IA, and negative or 
indeterminate antibody differentiation test to distinguish specimens with acute infection 
from false-positive IAs. Maryland PHL used validated in-house HIV-1 NATs and HIV-1/
HIV-2 conventional PCR assays, which were less expensive to run than commercial assays. 
PHLs without NAT that wish to use the recommended algorithm may need to partner with 
other PHLs or clinical sites with access to a NAT.
Our study is subject to a few limitations. Firstly, comparison across sites regarding the cost 
and time to reporting of test results may not be reliable because of variations in the HIV 
diagnostic algorithms used by the participating PHLs. Secondly, the analysis is based on 
specimens and not individuals; there may be instances where more than one specimen 
belongs to the same individual. Thirdly, although Maryland PHL used a different HIV 
testing algorithm than the recommended algorithm, they used fourth-generation IA, an 
HIV-1/HIV-2 differentiation antibody IA, and a HIV-1 NAT that helped identifying acute 
infections. Lastly, the information on time from specimen receipt to receipt of test results by 
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clients is missing for a large number of test results, therefore the results should be 
interpreted with caution.
To conclude, fourth-generation IA, coupled with antibody tests and NAT detected acute 
infections in PHLs that may have been missed if WB was the only confirmatory test in use. 
Algorithm costs were driven by the screening fourth-generation IA in the PHLs; reduction in 
their cost may help reduce the overall laboratory cost of diagnosing HIV infections. The 
identification of acute infection in PHLs can be coupled with public health intervention in 
order to interrupt disease transmission.
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HIV diagnostic testing algorithm of Massachusetts and Michigan Public Health 
Laboratories.
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HIV diagnostic testing algorithm of Maryland Public Health Laboratory.
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